WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The stability is led by healthy demand in the domestic and emerging markets
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
EMA’s CHMP advice states that Paxlovid can be used for treatment of adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease
Subscribe To Our Newsletter & Stay Updated
